HEPATIC DISORDERS IN PREGNANT WOMEN: A COMPLETE OVERVIEW OF CAUSES, SYMPTOMS, AND TREATMENTS

Pregnancy induces profound physiological adaptations to support the developing fetus, and the maternal liver is at the epicenter of these changes. It undergoes significant alterations in morphology, blood flow, and metabolic function. While most pregnancies proceed without hepatic complications, the intersection of gestation and liver disease presents unique diagnostic and therapeutic challenges. The evaluation of liver dysfunction in a pregnant patient requires a systematic approach that distinguishes between physiological adaptations, liver diseases unique to pregnancy (gestational hepatopathies), and coincidental pre-existing liver diseases that may be altered by gestation.

Failure to accurately diagnose and manage these conditions can lead to catastrophic outcomes for both the mother and the fetus, including preterm delivery, intrauterine growth restriction, fulminant hepatic failure, and maternal death.

Understanding Physiological Adaptations (The Baseline)

Before addressing pathology, one must understand the “normal” liver in pregnancy to avoid misdiagnosis. Many standard laboratory values change significantly during gestation.

• Hemodynamics: Cardiac output increases by 30-50%, leading to increased hepatic blood flow. This can sometimes cause a “hummingbird sign” on ultrasound, where the liver appears compressed by the enlarged uterus but is otherwise normal.
• Enzymes:
  • Alkaline Phosphatase (ALP): ALP levels can rise three to four times the normal limit due to placental isoenzyme production. To differentiate, one may look at Gamma-glutamyl transferase (GGT) levels, which remain normal in physiological pregnancy but are elevated in hepatobiliary disease.
  • Transaminases (ALT/AST): These remain within normal limits. Elevation is always pathological.
• Proteins: Serum albumin and total protein levels decrease due to hemodilution.
• Coagulation: Pregnancy is a hypercoagulable state. Fibrinogen levels increase significantly (often up to 600 mg/dL), while factors VII, VIII, X, and von Willebrand factor also rise. Physologic DIC (Disseminated Intravascular Coagulation) does not occur, but the stage is set for rapid pathological cascades.

Clinical Pearl: If a pregnant patient has elevated transaminases, it is not due to pregnancy; a specific etiology must be sought.

Categorizing Liver Disease in Pregnancy

To navigate this complex field, clinicians should categorize disorders based on whether they are:

1. Pre-existing: Chronic liver disease (e.g., Autoimmune Hepatitis, Viral Hepatitis, Cirrhosis) aggravated by pregnancy.
2. Gestational-Specific: Conditions unique to pregnancy (e.g., Hyperemesis Gravidarum, Intrahepatic Cholestasis of Pregnancy (ICP), Acute Fatty Liver of Pregnancy (AFLP), Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome, and Preeclampsia).

The following sections follow a clinical timeline.

The Antepartum Period (Weeks 1–40)

This is the most critical phase for diagnosing hepatic disorders. The presentation varies from mild pruritus to life-threatening failure.

A. Hyperemesis Gravidarum (HG)

• Timing: Usually weeks 8–12.
• Pathophysiology: High levels of Beta-hCG and thyroid hormones cause transient liver injury.
• Presentation: Severe nausea, vomiting, weight loss >5% of pre-pregnancy weight, dehydration, and ketosis.
• Liver Manifestations: Mild elevation of transaminases (ALT/AST up to 200 IU/L) and bilirubin. Jaundice is rare (occurring in <10% of cases).
• Management: Rehydration (IV fluids), antiemetics, and nutritional support. Liver enzymes typically normalize spontaneously by weeks 14–20.

B. Viral Hepatitis

Acute viral hepatitis is the most common cause of jaundice in pregnancy worldwide.

• Hepatitis A: Generally self-limiting; no evidence of vertical transmission. Supportive care is the standard.
• Hepatitis B: Vertical transmission is the primary concern. All pregnant women should be screened for HBsAg. If positive, the infant must receive Hepatitis B Immunoglobulin (HBIG) and the vaccine within 12 hours of birth to prevent chronic infection (90% reduction in transmission).
• Hepatitis C: Routine screening is recommended by the ACOG (American College of Obstetricians and Gynecologists). Vertical transmission occurs in approximately 5-6% of cases, higher if the mother is co-infected with HIV. Cesarean section is not recommended solely to prevent transmission.

C. Intrahepatic Cholestasis of Pregnancy (ICP)

This is the most common liver disorder specific to the second and third trimesters.

• Pathophysiology: Genetic mutations (e.g., ABCB4, ABCB11 genes) combined with high estrogen levels impair the transporter pumps in the hepatocyte canalicular membrane, causing bile acids to accumulate in the blood and liver.
• Presentation: Intense pruritus (itching), usually starting on the palms and soles, without a rash. Jaundice occurs in 10-20% of patients and appears 2-4 weeks after itching starts.
• Labs:
  • Total serum bile acids are the hallmark (normal is <10 µmol/L; ICP is usually >20 µmol/L).
  • ALT/AST are elevated (often 2-10 times normal).
  • Bilirubin is mildly elevated.
• Risks: Fetal distress, meconium staining, preterm birth, and sudden intrauterine fetal death (etiology unknown).
• Management:
  • Ursodeoxycholic Acid (UDCA): First-line therapy. It improves bile flow, reduces itching, and protects the fetus.
  • Vitamin K: Given prophylactically in late pregnancy to prevent maternal hemorrhage (malabsorption of fat-soluble vitamins).
  • Delivery: Most guidelines recommend delivery at 37 weeks (or earlier if bile acids are >40 µmol/L).

D. Acute Fatty Liver of Pregnancy (AFLP)

A rare but life-threatening metabolic disorder, usually occurring in the third trimester or early postpartum.

• Pathophysiology: Deficiency of the enzyme Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) in the fetus prevents the breakdown of fatty acids. The accumulation of fatty acids damages the maternal liver. It is associated with a fetus carrying the LCHAD mutation (often double heterozygous).
• Presentation: Malaise, fatigue, nausea, vomiting, right upper quadrant pain, headache, and polyuria/polydipsia (due to diabetes insipidus). It can rapidly progress to hepatic encephalopathy (confusion/coma).
• Labs (The Swansea Criteria):
  • Elevated transaminases (ALT/AST).
  • Elevated Ammonia (hallmark of severity).
  • Elevated Bilirubin.
  • Hypoglycemia (critical to check).
  • Elevated Uric Acid, WBC, and PT/INR.
  • Low Platelets.
  • Elevated LDH.
• Management:
  • Immediate Delivery: The only cure is delivery of the fetus and placenta.
  • Supportive ICU Care: Management of coagulopathy (FFP), hypoglycemia (Dextrose infusion), renal failure (dialysis), and encephalogy (lactulose).
  • Liver Transplant: Rarely needed if fulminant failure occurs.

E. Preeclampsia and HELLP Syndrome

Preeclampsia is a multisystem disorder of pregnancy characterized by hypertension and proteinuria after 20 weeks of gestation.

• HELLP Syndrome: A severe variant of Preeclampsia.
  • Hemolysis (Microangiopathic hemolytic anemia).
  • Elevated Liver enzymes.
  • Low Platelets.
• Presentation: Epigastric or right upper quadrant pain (due to Glisson’s capsule distension), nausea/vomiting, headache, and visual disturbances.
• Pathophysiology: Placental ischemia releases factors causing endothelial damage and activation of the coagulation cascade. This leads to fibrin deposition in sinusoids, causing liver ischemia and necrosis.
• Management:
  • Stabilization of the mother (Blood pressure control, Magnesium Sulfate for seizure prophylaxis).
  • Delivery: Definitive management. Timing depends on gestational age and severity. For remote preterm cases (<34 weeks), a “watch and wait” approach with close monitoring is sometimes used, but deterioration is rapid.
  • Corticosteroids: Used to improve platelet count and fetal lung maturity if delivery is imminent preterm.

Intrapartum Management (During Labor)

Managing a pregnant patient with hepatic dysfunction during delivery requires a multidisciplinary team (OB, Anesthesia, Hepatology, Neonatology).

1. Anesthesia Considerations:
   • Epidural/Spinal: Preferred for pain relief. However, in patients with coagulopathy (low platelets <70-100k or elevated INR), neuraxial anesthesia is contraindicated due to the risk of epidural hematoma. General anesthesia may be required.
2. Coagulopathy Management:
   • Patients with AFLP or severe HELLP often have DIC. Blood products (Platelets, FFP, Cryoprecipitate) should be readily available.
3. Mode of Delivery:
   • Vaginal delivery is preferred if the maternal and fetal conditions are stable.
   • Cesarean section is reserved for obstetric indications, fetal distress, or severe maternal instability where rapid delivery is necessary but vaginal delivery is not imminent.

The Postpartum Period (Up to 12 Weeks)

The postpartum period is a “danger zone.” While many conditions resolve immediately after placental delivery (AFLP, Preeclampsia), others may appear or worsen.

A. Postpartum Onset Preeclampsia/Eclampsia

Preeclampsia can develop for the first time up to 6 weeks postpartum (though rare after 48 hours). Patients discharged home with mild hypertension must be counseled on headache and visual symptoms.

B. Budd-Chiari Syndrome (BCS)

This is hepatic venous outflow obstruction.

• Why Postpartum? Pregnancy is hypercoagulable. A clot can form in the hepatic veins (often triggered by the oral contraceptive pill or postpartum state).
• Presentation: Acute abdominal pain, ascites, hepatomegaly, and jaundice.
• Management: Thrombolysis, TIPS (Transjugular Intrahepatic Portosystemic Shunt), or surgical shunting.

C. Pyelonephritis and Sepsis

While not a primary liver disorder, gram-negative sepsis (often from a urinary tract infection) can lead to “shock liver” (ischemic hepatitis), characterized by a rapid spike in transaminases (ALT/AST >1000) due to hypoperfusion.

Differential Diagnosis Strategy

When presented with a pregnant patient with abnormal liver tests, a stepwise approach is essential:

1. Is it physiological? (No, if ALT/AST elevated).
2. Is it viral? (Check viral serologies).
3. Is it biliary? (Ultrasound for stones). Gallstones are more common in pregnancy due to gallbladder hypomotility.
4. Is it gestational?
   • Early pregnancy: Hyperemesis.
   • Late pregnancy: ICP, Preeclampsia, HELLP, AFLP.
5. Is it autoimmune? (Check ANA, ASMA, IgG). Autoimmune hepatitis can flare during pregnancy.
6. Drug-Induced: Check for herbal supplements, antibiotics, and anti-nausea meds.

Conclusion

Hepatic disorders in pregnancy are high-stakes emergencies that require rapid recognition and intervention. The distinction between physiological changes and pathology is vital. The practitioner must have a low threshold for investigating abnormal liver function tests.

Key takeaways for management include:

• ICP requires UDCA and early delivery to prevent stillbirth.
• HELLP/AFLP requires immediate stabilization and delivery, often via cesarean section, followed by aggressive postpartum monitoring.
• Viral Hepatitis B requires immediate immunoprophylaxis for the newborn.

By adhering to a systematic, step-by-step diagnostic framework and utilizing a multidisciplinary team approach, maternal and fetal morbidity and mortality can be significantly reduced.

References

1. American College of Obstetricians and Gynecologists (ACOG). (2023). Practice Bulletin No. 222: Gestational Hypertension and Preeclampsia. Obstetrics & Gynecology, 141(6), 1371-1380.
2. American College of Obstetricians and Gynecologists (ACOG). (2019). Practice Bulletin No. 200: Intrahepatic Cholestasis of Pregnancy. Obstetrics & Gynecology, 134(5), e109-e115.
3. Kumar, R., & Sharma, P. (2020). Acute Fatty Liver of Pregnancy: A Review. Journal of Clinical and Experimental Hepatology, 10(1), 36-44.
4. Geenes, V., & Williamson, C. (2017). Intrahepatic cholestasis of pregnancy. World Journal of Gastroenterology, 15(20), 2673-2683.
5. Hay, J. E. (2009). Liver disease in pregnancy. Hepatology, 49(2), 675-686.
6. Sibai, B. M. (2005). Diagnosis, prevention, and management of eclampsia. Obstetrics & Gynecology, 105(2), 402-410.
7. Ch’ng, C. L., Morgan, M., & Hainsworth, I. (2002). Prospective study of liver dysfunction in pregnancy in Southwest Wales. Gut, 51(6), 876-880.
8. Riely, C. A. (2006). Liver disease in the pregnant patient. American Journal of Gastroenterology, 101(6), 1276-1282.